<DOC>
	<DOC>NCT02118168</DOC>
	<brief_summary>An observational study to prospectively follow-up the patients enrolled in the ISS T-002 clinical trial up to 132 weeks. The primary endpoint of this study is to evaluate the persistence, in term of frequency, magnitude and quality, of the anti-Tat humoral and cellular immune response in the HIV-1 infected individuals who participated to the ISS T-002 and who have received at least 3 immunizations. The secondary endpoint is to define and validate novel laboratory tests for future efficacy clinical trials.</brief_summary>
	<brief_title>Observational Study for the Extended Follow-up of the Patients Enrolled in the Therapeutic Clinical Trial ISS T-002</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Previous participation in the ISS T002 trial, having received at least 3 immunizations; A followup of at least 48 weeks during the ISS T002 study; Availability to participate in the extended followup study; Signed informed consent. The absence of any of the above criteria will exclude the subjects from the study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>HIV</keyword>
	<keyword>HAART</keyword>
	<keyword>Tat Protein</keyword>
</DOC>